| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 07/02/2002 | CA2047283C Pyrazolopyridine compound and processes for preparation thereof |
| 06/27/2002 | WO2002050287A2 Multifunctional protease inhibitors and their use in treatment of disease |
| 06/27/2002 | WO2002050270A1 Novel tissue-specific secretory polypeptide and dna thereof |
| 06/27/2002 | WO2002050255A2 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof |
| 06/27/2002 | WO2002050243A2 The use of ecm degrading enzymes for the improvement of cell transplantation |
| 06/27/2002 | WO2002050120A2 High affinity antibodies |
| 06/27/2002 | WO2002050115A1 Modified tachykinin receptors |
| 06/27/2002 | WO2002050071A1 Thiazolyl inhibitors of tec family tyrosine kinases |
| 06/27/2002 | WO2002050066A2 Pyrazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002050065A2 Pyrazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002050049A1 1,1-dioxo-2h-1, 2-benzothiazine-3-carboxamide derivatives, method for preparing same and pharmaceutical compositions comprising same |
| 06/27/2002 | WO2002050039A1 Urea and urethane derivatives as integrin inhibitors |
| 06/27/2002 | WO2002050034A2 Tetracyclic carbazole derivates and their use as spla2 inhibitors |
| 06/27/2002 | WO2002050033A1 Benzo(f) isoindol derivatives and their use as ep4 receptor ligands |
| 06/27/2002 | WO2002050032A1 Naphthalene derivatives which bind to the ep4 receptor |
| 06/27/2002 | WO2002050031A1 Indole derivatives |
| 06/27/2002 | WO2002050030A2 Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases |
| 06/27/2002 | WO2002050029A2 Tetracyclic derivatives as spla2 inhibitors |
| 06/27/2002 | WO2002050028A2 Substituted benzoindoles as spla2 inhibitors |
| 06/27/2002 | WO2002050021A1 Nitric oxide synthase inhibitor phosphate salt |
| 06/27/2002 | WO2002050019A2 Diamines as modulators of chemokine receptor activity |
| 06/27/2002 | WO2002049993A2 High affinity small molecule c5a receptor modulators |
| 06/27/2002 | WO2002049654A1 Shark meat extract |
| 06/27/2002 | WO2002049626A2 The use of ppar-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired pasticity |
| 06/27/2002 | WO2002049625A2 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds |
| 06/27/2002 | WO2002030353A3 NF-λB INHIBITORS |
| 06/27/2002 | WO2002026935A3 TGF-β INHIBITORS AND METHODS |
| 06/27/2002 | WO2002022602A3 Triazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002020822A3 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 06/27/2002 | WO2002020566A3 NOVEL MMP-2 DERIVATIVES FOR USE AS INHIBITORS OF INTEGRIN αVβ¿3? |
| 06/27/2002 | WO2002015881A3 Use of a porous carrier |
| 06/27/2002 | WO2002008231A3 Biologically active macrolides, compositions, and uses thereof |
| 06/27/2002 | WO2002003992A3 Use of substituted indole compounds for treating prosthesis-related bone degeneration |
| 06/27/2002 | WO2001097788A3 Method of administering bisphosphonates |
| 06/27/2002 | WO2001096298A3 1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase |
| 06/27/2002 | WO2001094381A3 Novel compounds of the n-acylamino-amide family, compositions comprising same, and uses |
| 06/27/2002 | WO2001087938A3 Polynucleotide sequence encoding a putative cell adhesion molecule |
| 06/27/2002 | WO2001076584A3 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases |
| 06/27/2002 | WO2001073025A3 Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains |
| 06/27/2002 | WO2000056350A9 Methods of use of beta 1-integrin inhibitors |
| 06/27/2002 | WO2000056348A9 Inflammatory mediation obtained from atractylodes lancea |
| 06/27/2002 | US20020082435 For use in cancer therapy |
| 06/27/2002 | US20020082388 Polypeptide for use in the treatment, diagnosis and prevention of cancer, nervous system and developmental disorders |
| 06/27/2002 | US20020082279 Topical mixture of a carrier, essential oil, and a conventional dermatologic active ingredient |
| 06/27/2002 | US20020082276 Quinoline derivatives as anti-inflammatory agents |
| 06/27/2002 | US20020082269 Purine-2,6-dione based compounds as receptor binding assay probes and pharmaceuticals; high potency and affinity with water solubility |
| 06/27/2002 | US20020082266 Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore |
| 06/27/2002 | US20020082258 Novel antitobesity and hypocholesterolemic compounds lower total cholesterol; increase high density lipoprotein (HDL) and decrease low denstiy lipoprotein |
| 06/27/2002 | US20020082256 Compounds useful as anti-inflammatory agents |
| 06/27/2002 | US20020082246 Prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading enzymes is involved; these include degenerative joint disorders such as osteoarthroses and disorders of connective tissue |
| 06/27/2002 | US20020082244 Compositions and methods for inhibiting bone resorption |
| 06/27/2002 | US20020082235 Inhibition of binding of hox and homeodomain-containing proteins and uses thereof |
| 06/27/2002 | US20020082230 Introducing an antisense oligomer into a cell, allowing the oligomer to hybridize to the mRNA of IL-15, thereby inhibiting the production of IL-15 |
| 06/27/2002 | US20020082221 Nitric-oxide releasing lipid molecules selected from phosphoglycerides, lipids having a sphingosine base as a backbone, a monoglyceride, a diglyceride, a glycosylacylglycerol and a sterol containing S-N=O, N-N=O or |
| 06/27/2002 | US20020081719 Inflammation inducible hybrid promoters, vectors comprising them and uses thereof |
| 06/27/2002 | US20020081695 Nucleotide sequences coding polypeptide for use in the treatment of blood disorders, gout, kidney stones, Lesch-Nyhan syndrome, renal failure and uricaciduria |
| 06/27/2002 | US20020081296 Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3 and TACI |
| 06/27/2002 | US20020081290 Protein kinase homologs |
| 06/27/2002 | US20020081288 A polypeptide selected from the group consisting of a SOD-4 polypeptide (superoxide dimutase) having a preferred deduced amino acid sequence and fragments, analogs and derivatives encoded by a specific polynucleotide |
| 06/27/2002 | CA2433018A1 Thiazolyl inhibitors of tec family tyrosine kinases |
| 06/27/2002 | CA2432908A1 Diamines as modulators of chemokine receptor activity |
| 06/27/2002 | CA2432807A1 1,1-dioxo-2h-1, 2-benzothiazine-3-carboxamide derivatives, method for preparing same and pharmaceutical compositions comprising same |
| 06/27/2002 | CA2432760A1 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof |
| 06/27/2002 | CA2432157A1 The use of ecm degrading enzymes for the improvement of cell transplantation |
| 06/27/2002 | CA2431721A1 Tetracyclic derivatives as spla2 inhibitors |
| 06/27/2002 | CA2431446A1 High affinity antibodies |
| 06/27/2002 | CA2431028A1 Tetracyclic carbazole derivates and their use as spla2 inhibitors |
| 06/27/2002 | CA2431023A1 Substituted benzoindoles as spla2 inhibitors |
| 06/27/2002 | CA2430973A1 Multifunctional protease inhibitors and their use in treatment of disease |
| 06/27/2002 | CA2430918A1 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds |
| 06/27/2002 | CA2430808A1 Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases |
| 06/27/2002 | CA2423331A1 Shark meat extract |
| 06/26/2002 | EP1217002A1 2-(4-pyridinyl)-benzofurans as metalloprotease inhibitors |
| 06/26/2002 | EP1216309A2 Methods for targeting rna molecules |
| 06/26/2002 | EP1216257A1 Compounds for the treatment of ischemia |
| 06/26/2002 | EP1216245A1 Pharmaceutically active sulfonyl hydrazide derivatives |
| 06/26/2002 | EP1216241A1 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 06/26/2002 | EP1216240A1 Amide compounds |
| 06/26/2002 | EP1216238A2 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 06/26/2002 | EP1216234A2 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 06/26/2002 | EP1216232A1 Heterocyclic compounds and methods for modulating cxcr3 function |
| 06/26/2002 | EP1216230A2 Fused cycloheptane and fused azacycloheptane compounds and their use as integrin receptor antagonists |
| 06/26/2002 | EP1216067A1 Polyhydroxyalkanoate compositions for soft tissue repair, augmentation, and viscosupplementation |
| 06/26/2002 | EP1216057A1 Stable calcitriol solution for packaging in vials |
| 06/26/2002 | EP1216030A1 Anti-inflammatory pharmaceutical formulations |
| 06/26/2002 | EP1216024A1 Formulation for menopausal women |
| 06/26/2002 | EP1007072A4 Glial cell line-derived neurotrophic factor receptors |
| 06/26/2002 | EP0998288B1 Compositions containing capsaicin or capsaicin analogues and a local anesthetic |
| 06/26/2002 | EP0906120B1 Compositions comprising a combination of bone morphogenetic protein and parathyroid hormone-related peptide |
| 06/26/2002 | EP0904094A4 Treatment of bone disorders with adrenomedullin |
| 06/26/2002 | EP0894084B1 Cinnamic acid derivatives and their use as integrin antagonists |
| 06/26/2002 | EP0771206B1 Hard tissue stimulating agent |
| 06/26/2002 | EP0691814B1 Method and composition for treatment of osteoporosis |
| 06/26/2002 | CN1355881A Growth differentiation factor inhibitors and uses therefor |
| 06/26/2002 | CN1355852A T cell receptor Vbeta-Dbeta-Jbeta sequence and methods for its detection |
| 06/26/2002 | CN1355811A Integrain receptor antagaonists |
| 06/26/2002 | CN1355799A 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives |
| 06/26/2002 | CN1355714A LIM Mineralization protein splice variants |
| 06/26/2002 | CN1355702A Use of arylalkanoylpyridazines |
| 06/26/2002 | CN1355697A IL-8 receptor antagonists |